-67.4%
IREN vs GSK
+14.9%
-82.3%
-71.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -11.2% | +5.0% | -16.3% | -6.5% |
| 7D | -24.7% | +4.9% | -29.7% | -20.6% |
| 30D | -46.4% | +9.9% | -56.3% | -40.8% |
| 3M | -46.9% | +0.2% | -47.0% | -45.2% |
| 6M | -56.1% | +2.3% | -58.4% | -53.6% |
| YTD | -42.5% | +7.1% | -49.6% | -28.0% |
| 1Y | -67.4% | +13.1% | -80.5% | -56.5% |
| All | -67.4% | +14.9% | -82.3% | -56.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling